Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
The use of hydroxychloroquine for COVID-19 treatment and prevention should be restricted in both out- and inpatient settings due to the lack of evidence for effectiveness and unfavorable safety profile.
Saved in:
Main Authors: | K. B. Mirzaev (Author), D. A. Sychev (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020) -
What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020) -
Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020) -
Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020) -
Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020)